NEW YORK , June 12, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the appointment of Kathryn A. Kornafel as vice president of Marketing and Commercial Development.
“Kathryn’s extensive marketing experience within the diagnostic, cardiovascular and point-of-care arenas position her to support Daxor’s aggressive sales goals,” said Michael Feldschuh, CEO of Daxor. “We look forward to leveraging her more than 25 years of experience to drive awareness and educate healthcare professionals regarding our proven 98 percent accurate BVA-100®. Clinical studies have demonstrated strong patient outcomes from blood volume-guided therapy in heart failure and critical care.”
Before joining Daxor, Kathryn has held leadership roles in global marketing, business development, and sales with major international IVD medical device companies, including HemoCue and Ortho Clinical Diagnostics. In addition to her business experience, Kathryn is an American Society of Clinical Pathology-certified Medical Technologist with clinical lab experience in hematology and microbiology. She holds a bachelor degree in Biology from University of Delaware and a Bachelor of Science degree in Medical Technology from Thomas Jefferson University.
Daxor Corporation is an innovative commercial-stage medical instrumentation and biotechnology company. The company manufactures the BVA-100 Blood Volume Analyzer, the only instrument cleared by the FDA to provide rapid direct measurement of a patient’s blood volume and optimal volume. Its mission is to help hospitals and physicians incorporate Daxor’s advanced technologies to significantly improve the quality of patient care. For more information please visit our website at http://www.daxor.com.
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Sr. Managing Partner